Structure of therapy and compliance of patients with severe arterial hypertension

Структура терапии и приверженность больных с тяжелым течением артериальной гипертензии
Aigerim Mussina 1, Raikhan Tuleutayeva 1, Natalya Cebotarenko 2, Matthias Hammerer 3, Assem Makhatova 4, Laura Pak 5
More Detail
1 Semey State Medical University, Pharmacology and evidence-based medicine department, Semey, Kazakhstan
2 World Health Organization, Coalition on Rational drug Use CORSUM. Chisinau, Moldova
3 University Hospital of Salzburg, Department of Internal Medicine II. Salzburg, Austria
4 Semey State Medical University, Pharmacology and evidence-based department, Semey, Kazakhstan
5 Semey State Medical University, Oncology and visual diagnosis department, Semey, Kazakhstan
J CLIN MED KAZ, Volume 2, Issue 44, pp. 36-41. https://doi.org/10.23950/1812-2892-JCMK-00390
OPEN ACCESS 3760 Views 2342 Downloads
Download Full Text (PDF)

ABSTRACT

The purpose of the study was to determine the structure, compliance to antihypertensive pharmacotherapy in patients with arterial hypertension of the third degree in the conditions of Semey and the frequency of achieving target BP.
The study included 618 patients with hypertension III degree. The age of patients ranged from 38 to 77 years (mean age - 61,2 ± 2,7 years). Among the surveyed men was -353, women - 265.
Carried out an analysis of medical records and patient survey to determine the structure of antihypertensive therapy, compliance to it and the existing violations preparations reception mode.
Was revealed prevalence in the appointment’s structure the combinations of antihypertensive drugs (46.0%) and fixed combinations (29.0%). Monotherapy performed more frequently with beta-blockers and calcium channel antagonists.
It revealed the greatest compliance to the use of fixed combinations of drugs and most high clinical efficacy of antihypertensive therapy options.
Keywords: arterial hypertension, pharmacotherapy, compliance

CITATION

Mussina A, Tuleutayeva R, Cebotarenko N, Hammerer M, Makhatova A, Pak L. Structure of therapy and compliance of patients with severe arterial hypertension. Journal of Clinical Medicine of Kazakhstan. 2017;2(44):36-41. https://doi.org/10.23950/1812-2892-JCMK-00390

REFERENCES

  • Leeman M.Management of severe arterial hypertension. Rev Med Brux. 2015; 36(4): 373-376.
  • Mitaka H., Yamada Y., Hamada O.et al.Malignant Hypertension with Thrombotic Microangiopathy. Intern Med. 2016; 55(16): 2277-2280.
  • Lobodzinski S.S.New developments in the treatment of severe drug resistant hypertension. Cardiol J. 2011; 18(6): 707-711.
  • Hwang A.Y., Dave C., Smith S.M.Trends in Antihypertensive Medication Use Among US Patients With Resistant Hypertension, 2008 to 2014. Hypertension. 2016; 68(6): 1349-1354.
  • Mallat S.G., Tanios B.Y., Itani H.S.et al.Free versus Fixed Combination Antihypertensive Therapy for Essential Arterial Hypertension: A Systematic Review and Meta-Analysis. PLoS One. 2016; 11(8) – 0161285.
  • Kozlovskij V.I., Simanovich A.V. Priverzhennost’ k terapii u pacientov s arterial’nojgipertenziej II stepeni. Obzorliteraturyisobst vennyedannye. Vestnik VGMU. 2014; 13(2) :6-16.
  • Val Jiménez A., AmorósBallestero G., Martínez Visa P., FernándezFerré M.L., León Sanromà M.Descriptive study of patient compliance in pharmacologic antihypertensive treatment and validation of the Morisky and Green test. Aten Primaria. 2002; 10(5): 767-770.
  • Nacionalnyeklinicheskierekomendacii: sbornik / pod red. R.G. Oganova. - 3-e izd. - Moskva: Siliceya-Poligraf, 2010. - 592 s.
  • Chapman R.H. Predictors of adherence with antihypertensive andlipid-lowering therapy. Arch Intern Med. 2005; 165(10): 1147- 1152.
  • Hohlov A.L., Lisenkova L.A., Rakov A.A. Analizfaktorov, opredelyayushhixpriverzhennost k antigipertenzivnojterapii. Kachestvennaya klinicheskaya praktika. 2003; 4: 59-66.
  • Serov V.A., Gorbunov V.I. Vliyanie socialno-ekonomicheskix faktorov napriverzhennost k lecheniyu bolnyx gipertonicheskoj boleznyu. Klinicheskaya medicina. 2007; 85(3): 65-68.
  • Konradi A.O., Polunicheva E.V. Nedostatochnaya priverzhennost k lecheniyu arterialnoj gipertenzii: prichinyiputikorrekcii. Arterialnaya gipertenziya. 2004; 10(3): 137-143.
  • Rekomendacii polecheniyu arterialnoj gipertonii Evropejskogo obshhestva po gipertonii (ESH) i Evropejskogo obshhestva kardiologov (ESC). 2013: 45.
  • Weber M.A., Julius S., Kjeldsen S.E. et al. Cardiovascular outcomes in hypertensive patients: comparing singleagent therapy with combination therapy. J Hypertens. 2012; 30: 2213-2222.